Gilead Sciences (GILD) Tops Q3 EPS by 94c

Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.65, $0.94 better than the analyst estimate of $1.71. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $6.18 billion.

GUIDANCE:

Gilead Sciences sees FY2021 EPS of $7.90-$8.10, versus the consensus of $7.18. Gilead Sciences sees FY2021 revenue of $26-26.3 billion, versus the consensus of $25.12 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping takeover bid as undervalued
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform